5 replies to this topic

[ihatesnow]

http://abcnews.go.co...tory?id=9212102

[Gerald W. Gaston]

http://abcnews.go.co...tory?id=9212102

This article from April 2008 talks a little more about it:
http://www.drugs.com...ented-3822.html

Dr. Norrie Russell, president and CEO of Kalos, said, "We are very encouraged by these study results, particularly in light of the National Cancer Institute analysis showing that an anti-cancer compound's breadth of activity in xenograft animal models is the best predictor of activity in human clinical studies. Based on these findings, and on the previous safe administration of KT-220 and other ANP family members to humans for another indication, we can confidently move forward with clinical development. Kalos is currently raising capital from institutional investors and qualified private individuals to initiate clinical trials of KT-220 in cancer."

KT-220 and the other peptides of the ANP family exert their anti-cancer effects through a novel mechanism involving the inhibition of the Mitogen Activated Protein Kinase (MAPK) signaling pathway, a key mechanism in cancer cell proliferation. These peptide hormones selectively shut off the proliferative effects of this kinase pathway in cancer cells but not in normal cells.

About the ANP Family of Peptides

The ANP family of peptides consists of four peptides derived from the pro-ANP gene, and includes ANP itself. These peptides, which share certain structural features, act through cell surface receptors to produce their antiproliferative effects. These peptides occur at the highest concentration in the heart, and much lower levels throughout the body. High natural levels of ANP peptides in the heart may be responsible for the low incidence of metastatic as well as primary cardiac tumors.

About Kalos Therapeutics

Kalos Therapeutics is a biopharmaceutical company that in-licenses, develops and commercializes proprietary product candidates primarily for the treatment of cancer. The ANP family of peptides represents a portfolio from which many drugs can be developed addressing multiple indications within cancer and non-malignant hyperproliferative disorders. More information can be found on Kalos' web site at http://www.kalostherapeutics.com.

And from http://www.kalostherapeutics.com:

Safe and Effective in Humans.
The ANP family of peptides consists of 4 natriuretic peptides produced by the heart that have well-known physiological effects such as salt excretion, diuresis, and vasodilation. Because of these antihypertensive effects, they were first used in humans as a treatment for congestive heart failure. These peptides are commonly administered intravenously and have produced no known serious adverse effects.

New Mechanism for the Treatment of Cancer.
KT-220, our lead drug candidate from the ANP family of peptides, regulates cell growth via inhibition of the mitogen-activated protein kinase (MAPK) pathway. As an endogenous peptide acting through a natural mechanism, KT-220 can produce broader anti-cancer activity than small molecules without the associated side effects. ANP peptides are designed by nature to inhibit the MAPK pathway by controlling initiation of the signaling cascade while synthetic drugs block only specific parts of the pathway. Supporting the inherent anti-cancer properties of ANP is the rarity of primary and metastatic cancers in the heart, where these peptides are at their highest concentrations.

Remarkable Anti-Cancer Activity.
KT-220 demonstrates remarkably broad anti-cancer activity. KT-220 has inhibited the growth of pancreatic, lung, prostate, breast, ovarian, colon, and melanoma cells in culture and of pancreatic, breast, and lung cancer tumors in models of human cancer.

Let's just hope they get funding soon and find a way to make a 'killing' off KT-220 or it will go no where like apparently everything else that sounds so promising.

Edited by frankbuzin, 02 December 2009 - 04:36 AM.

[ihatesnow]

http://news.yahoo.co..._20091207190020

[Logic]

New Israeli Cancer Vaccine Triggers Response In 90% Of Cancer Types

 

"...ImMucin works by stimulating a part of the immune system and teaching it to attack certain cells with certain markers that indicate the presence of cancer. When the drug is introduced during an early stage of cancer, the hope is that as a patient’s cancer begins to creep back, the immune system is trained appropriately to know which cells to destroy and which to leave be..."

 

http://nocamels.com/...ine-for-cancer/

[Logic]

Cure for cancer might accidentally have been found, and it could be malaria

http://www.independe...a-a6693601.html

[Logic]

...derivatives of the chemical phenanthridine - end up disrupting the spindle, preventing cell chromosomes from splitting, and stopping the cell from dividing....

http://www.scienceal...o-self-destruct